| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |